Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Proteomic Investigation of the Signal Transduction Pathways Controlling Colistin Resistance in Klebsiella pneumoniae

Ching Hei Phoebe Cheung, Punyawee Dulyayangkul, Kate J. Heesom, Matthew B. Avison
Ching Hei Phoebe Cheung
aSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Punyawee Dulyayangkul
aSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate J. Heesom
bUniversity of Bristol Proteomics Facility, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Avison
aSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew B. Avison
DOI: 10.1128/AAC.00790-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Colistin resistance in Klebsiella pneumoniae is predominantly caused by mutations that increase expression of the arn (also known as pbg or pmrF) operon. Expression is activated by the PhoPQ and PmrAB two-component systems. Constitutive PhoPQ activation occurs directly by mutation or following loss of MgrB. PhoPQ may also cross-activate PmrAB via the linker protein PmrD. Using proteomics, we show that MgrB loss causes a wider proteomic effect than direct PhoPQ activation, suggesting additional targets for MgrB. Different mgrB mutations cause different amounts of Arn protein production, which correlated with colistin MICs. Disruption of phoP in an mgrB mutant had a reciprocal effect to direct activation of PhoQ in a wild-type background, but the regulated proteins showed almost total overlap. Disruption of pmrD or pmrA slightly reduced Arn protein production in an mgrB mutant, but production was still high enough to confer colistin resistance; disruption of phoP conferred wild-type Arn production and colistin MIC. Activation of PhoPQ directly or through mgrB mutation did not significantly activate PmrAB or PmrC production, but direct activation of PmrAB by mutation was able to do this, and also activated Arn production and conferred colistin resistance. There was little overlap between the PmrAB and PhoPQ regulons. We conclude that under the conditions used for colistin susceptibility testing, PhoPQ-PmrD-PmrAB cross-regulation is not significant and that independent activation of PhoPQ or PmrAB is the main reason that Arn protein production increases above the threshold required for colistin resistance.

INTRODUCTION

Colistin is increasingly used to treat infections caused by extensively drug resistant Gram-negative bacteria (1). Colistin resistance in carbapenem-resistant Klebsiella pneumoniae, which was first reported in 2010 (2–4) is, therefore, a critically important problem. It can be caused by mobile mcr genes, but by far the most common causes in K. pneumoniae and some other Enterobacteriaceae species are chromosomal mutations (5, 6). For example, loss-of-function mutations in mgrB regularly emerge following colistin therapy in the clinic, and when selecting resistant mutants in the laboratory (7–10). Loss of MgrB causes activation of arn operon expression (7). This operon, also referred to as the pbg or pmrF operon (5), encodes a series of enzymes forming a pathway that modifies lipid A in lipopolysaccharide by adding 4-amino-4-deoxy-l-arabinose. This modification has been seen in colistin-resistant K. pneumoniae mutants in many studies (e.g., 11–13). Its effect is to reduce cell surface negative charge, reducing affinity for positively charged colistin, thereby raising its MIC (5).

Activation of arn operon transcription in K. pneumoniae involves two upstream promoters, each targeted by a two-component system response regulator. PhoP targets promoter 1 in response to low magnesium concentrations and PmrA targets promoter 2 in response to high iron concentrations and low pH (14). The dramatic impact that cations and pH have on arn promoter activity explains the wide range of medium-dependent colistin MICs observed in the laboratory (15, 16). According to a joint CLSI and EUCAST report, colistin susceptibility testing needs to be tightly standardized, therefore, and the gold standard is broth microdilution using colistin sulfate, cation-adjusted Muller Hinton broth (CAMHB) and with no additives (17).

Additional complexity arises in control of arn operon transcription in K. pneumoniae because the response regulator PhoP can also activate transcription of pmrD and PmrD binds PmrA and enhances its activation (14, 18). Hence, when low magnesium and high iron occur at the same time, the PmrA-targeted arn operon promoter 2 is more strongly activated than it is in the presence of high magnesium and high iron (14).

The cognate sensor kinases activating PhoP and PmrA are PhoQ and PmrB, respectively (14). It is generally accepted that loss-of-function mutations in mgrB activate arn operon transcription in K. pneumoniae because MgrB is a direct negative regulator of PhoQ sensor kinase activity, as in some other Enterobacteriaceae species (5). In fact, this is experimentally confirmed only in Salmonella spp. (19), but loss of MgrB does constitutively activate PhoPQ in K. pneumoniae, leading to constitutively enhanced transcription from arn operon promoter 1 (14). Specific mutations in PhoPQ also activate arn operon transcription and confer colistin resistance or heteroresistance in K. pneumoniae, e.g., PhoQ substitutions Asp434Asn (20) or Ala21Ser (21) or PhoP substitution Asp191Tyr (22).

Mutations in PmrAB that constitutively activate arn operon transcription from promoter 2 have also been found to cause colistin resistance in K. pneumoniae. For example, Leu82Arg (23) or Thr157Pro (24) in PmrB, but activation of PmrAB also increases expression of pmrC. This encodes an enzyme that modifies lipopolysaccharide by decorating it with phosphoethanolamine, which contributes to colistin resistance in Salmonella spp. because it is another way to reduce negative charge on the cell surface (25).

A third two-component regulatory system known to be involved in colistin resistance in K. pneumoniae is CrrAB. Activatory mutations in the sensor kinase CrrB have been identified in colistin-resistant clinical isolates (20, 26, 27). Based on transcriptomic analysis, these mutants have increased arn operon and pmrC transcription (20) and in this they closely resemble PmrAB activatory mutants and, indeed, pmrAB is essential for the activation of arn operon and pmrC transcription in CrrAB activatory mutants, suggesting direct linkage between these two-component systems (26). One additional effect of CrrAB activation is upregulation of crrC transcription (20), and crrC is also essential for activation of arn operon and pmrC transcription in a CrrAB activatory mutant (26). This suggests that CrrC forms the link between activated CrrAB and activation of PmrAB, leading to colistin resistance, but the mechanism by which this link operates is not yet known.

The complexity associated with acquisition of colistin resistance in K. pneumoniae means that clinical cases involve a wide range of mutations. In a recent large clinical survey, mgrB loss of function was the most common mechanism, but in many cases, additional mutations in two-component system genes was seen, and in cases where multiple mutations were seen, a sequential increase in colistin MIC was observed (28).

The aim of the work reported here was to use liquid chromatography-tandem mass spectrometry (LC-MS-MS) shotgun proteomics and targeted mutagenesis to investigate the importance of the MgrB-PhoPQ-PmrD-PmrAB signal transduction pathway to modulate Arn protein and PmrC production, and assess the protein abundance thresholds required for colistin resistance in K. pneumoniae stimulated by mutations affecting PhoPQ and/or PmrAB activity.

RESULTS AND DISCUSSION

Direct role of PhoPQ and the indirect role of signal transduction from PhoPQ through PmrD to PmrAB in Arn protein production and colistin resistance caused by mgrB mutation.A collection of six K. pneumoniae spontaneous single-step mutants were selected in the laboratory using Muller-Hinton agar containing 32 μg · ml−1 of colistin, and in each case, PCR and whole-genome sequencing confirmed only mutations in mgrB or upstream. Three different mutations were seen, causing the following changes: Gln29STOP in MgrB (found in four colistin-resistant mutants here, represented by mutant P21); an A to G transition at −31 relative to the mgrB start codon, weakening a putative second −10 promoter sequence (Fig. S1) (represented by mutant P22); a deletion comprising the region between −19 relative to the start codon, to remove the first 41 amino acids of MgrB (represented by mutant P23).

Colistin MICs against these three representative mutants were determined and, in all cases, colistin resistance was confirmed (Table 1). Envelope proteomics identified 45 proteins significantly differentially regulated in all three mgrB mutants relative to the parent strain, Ecl8 (33 up- and 12 downregulated; Table S1). These included the ArnABCDT operon proteins known to be responsible for modification of lipopolysaccharide by the addition of 4-amino-4-deoxy-l-arabinose (5). Figure 1 shows that Arn protein production is highest in the mutant P23, where MgrB is entirely lost. The mgrB nonsense mutant truncated at 29 amino acids, P21, and the mgrB promoter mutant P22 both have significantly lower Arn protein production than in P23, implying some residual repressive activity of MgrB in both cases. Overall, P22 had the lowest Arn protein production of the three (Fig. 1). Nonetheless all three mutants are colistin resistant though, as expected based on Arn protein production levels, the highest MIC is against P23 and the lowest against P22 (Table 1). This leads to the conclusion that once Arn protein production increases above a certain threshold, colistin resistance is conferred, but that as protein production increases further (P23 > P21 > P22), MIC also increases.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

MICs of colistin against clinical isolates and mutant derivatives

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Arn protein abundance in parent strain Ecl8 versus three mgrB mutants. Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein in a sample are presented, normalized using the average abundance of the 50 most abundant proteins in that sample. Data for three biological replicates of parent (Ecl8) and mgrB mutants (P21, P22 and P23) are presented as mean ± standard error of the mean. All mutants have statistically significantly increased production of all Arn proteins relative to Ecl8 based on a t test (P < 0.05).

It has been proposed that, in K. pneumoniae, arn operon gene expression is increased upon mgrB mutation through activation of the two-component system PhoPQ, and that, in addition, there is a secondary increase through activation of the PmrAB two-component system, with PmrD being necessary for transducing PhoPQ activation into PmrAB activation (5). Using mgrB mutant P23 as a starting point, we disrupted phoP, pmrD, and pmrA to test the effects of these mutations on Arn protein production and colistin MICs.

Observed Arn protein abundance changes in these regulatory mutants demonstrated the primacy of PhoPQ activation in colistin resistance driven by mgrB loss. Arn protein abundance returned to wild type (Fig. 2) and the colistin MIC fell below the resistance breakpoint (Table 1) upon disruption of phoP in the mgrB mutant P23. In contrast, our proteomics analysis (Fig. 2) showed that PmrD and PmrAB play only a minor role in increased Arn protein production seen in an mgrB mutant. Only ArnC significantly reduced in abundance following disruption of pmrA. There was a larger effect following disruption of pmrD (four out of five Arn proteins significantly reduced in abundance), but in neither mutant did any of the Arn proteins fall in abundance significantly below levels seen in the mgrB mutants P21 and P22 (Fig. 1) and, not surprisingly therefore, the pmrA and pmrD mutant derivatives of mgrB mutant P23 remained colistin resistant (Table 1). These data add support for our conclusion that there is a threshold of Arn protein abundance required for colistin resistance. It seems clear that PhoPQ activation alone can support an abundance above this threshold even without any additional effects caused by PmrAB activation.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Arn protein abundance in mgrB loss-of-function mutant P23 versus its phoP, pmrD, and pmrA loss-of-function mutant derivatives. Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein in a sample are presented, normalized using the average abundance of the 50 most abundant proteins in that sample. Data for three biological replicates of parent (P23) and mutants where phoP, pmrD, or pmrA had been insertionally inactivated (PhoP−, PmrD−, or PmrA−) are presented as mean ± standard error of the mean. All PhoP− mutants have statistically significantly reductions in production of all Arn proteins relative to P23 based on a t test (P < 0.05). For PmrD− and PmrA− mutants, significant changes relative to P23 were seen, respectively, for ArnD, -A, -C and -B, or ArnC only.

PhoPQ-regulated proteins identified following mgrB mutation and PhoQ activation.Of 45 proteins (i.e., including the Arn proteins) differentially regulated in all three mgrB mutants (Table S1), 18 of those upregulated in the mgrB mutant P23 returned to wild-type levels upon disruption of phoP (Table 2). These included the five Arn proteins, the response regulator PhoP itself, LpxO, and two Mg2+ transporters, including MgtA, SlyB and MacA. Transcripts representing all these proteins have been seen to be upregulated in mgrB loss-of-function and in PhoQ activatory (PhoQ*) colistin-resistant clinical isolates relative to colistin-susceptible control isolates through transcriptomics (20). Our proteomics analysis reinforces the definition of a core PhoPQ regulon, but a secondary observation is that the majority (27/45) of the protein abundance changes seen in the mgrB mutant P23 (Table S1) do not occur via activation of PhoPQ, i.e., they were not reversed following disruption of phoP (Table 2). The implication of this finding, made here by comparing otherwise isogenic pairs of strains, is that MgrB interacts with regulatory networks other than PhoPQ in K. pneumoniae, though these additional effects are not important for colistin resistance, which was completely reversed following disruption of phoP (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

Significant changes in envelope protein abundance seen in K. pneumoniae mutant P23 phoP versus P23a

In order to further investigate the role of direct PhoPQ activation in colistin resistance, we turned to a colistin-resistant, PhoQ* (activatory) mutant that we selected from K. pneumoniae clinical isolate KP47 (Table 1). Whole-genome sequencing identified the mutation causes a Tyr89Asn change in PhoQ. Proteomics comparing KP47 with the PhoQ* mutant derivative revealed that levels of Arn protein production in the PhoQ* mutant were not significantly different from those in the mgrB loss-of-function mutant P23 (Fig. 3). Indeed, despite starting with a different parent strain, significant upregulation of 15/18 proteins seen to become downregulated when phoP was disrupted in the Ecl8-derived mgrB mutant P23 were also upregulated in the PhoQ* mutant relative to its parent, KP47. This further focused down onto the core K. pneumoniae PhoPQ regulon, which is shown in Table 2.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Arn protein abundance in mgrB mutant P23 versus clinical isolate KP47 and PhoQ* or PmrB* (activatory) mutant derivatives. Strains were grown in CAMHB and raw envelope protein abundance data for each Arn protein in a sample are presented, normalized using the average abundance of the 50 most abundant proteins in that sample. Data for three biological replicates of parent (KP47) and mutants where PhoQ or PmrA have been activated, compared with the mgrB loss-of-function mutant P23 are presented as mean ± standard error of the mean. All Arn proteins, and all Arn proteins except ArnB, were significantly upregulated relative to KP47 in its PhoQ* mutant and PmrB* mutant, respectively, based on a t test (P < 0.05). For the PmrB* mutant, significantly lower abundances relative to the PhoQ* mutant were seen for ArnA and ArnB.

Proteins upregulated following activation of PmrAB.It has been reported that PmrAB activation directly by mutation can confer colistin resistance (23, 24) and we were able to select a colistin-resistant mutant of clinical isolate KP47 with an activatory mutation in PmrB (Table 1). The mutation identified using whole-genome sequencing was Thr157Pro. Arn protein abundance in this PmrB* mutant was significantly elevated relative to KP47 in all cases except for ArnB. For all except ArnA and ArnB, the extent of abundance increase was like that seen in the PhoQ* derivative of KP47, and the mgrB mutant P23 (Fig. 3). In total, however, only 7/45 proteins significantly up- or downregulated in the mgrB mutant P23 were significantly up- or downregulated in the PmrB* mutant. As well as the Arn proteins (except ArnB), these were SlyB, LpxO, and one Mg2+ transporter, which are all part of the core PhoPQ regulon (Table S1). Transcripts representing all seven of these PrmAB/PhoPQ dual regulated proteins, plus ArnB, have also been seen to be upregulated in clinical isolates with activatory mutations in CrrB (20), which indirectly activates PmrAB (26, 27).

The fact that ArnB abundance did not increase significantly above the level seen in wild-type KP47 was surprising since the PmrB* mutant is colistin resistant (Table 1). This suggested that either significant upregulation of ArnB is not essential for colistin resistance or there is another mechanism involved in colistin resistance in the PmrB* mutant. To identify a possible additional mechanism, we searched the 65 proteins differentially regulated in the PmrB* mutant relative to KP47. Three of those most strongly overproduced were PmrA, PmrB, and PmrC (Fig. 4). Transcription of pmrC (also known as eptA) is known to be positively controlled by PmrAB in K. pneumoniae (24). In Salmonella spp. it encodes a phosphoethanolamine transferase, responsible for modifying lipopolysaccharide by decorating it with phosphoethanolamine, and this increases the MIC of colistin (25).

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

PmrA, B, C, and E protein abundance in mgrB mutant P23 versus clinical isolate KP47 and PhoQ* or PmrB* (activatory) mutant derivatives. Strains were grown in CAMHB and raw envelope protein abundance data for each Pmr protein in a sample are presented, normalized using the average abundance of the 50 most abundant proteins in that sample. Data for three biological replicates of parent (KP47) and mutants where PhoQ or PmrA have been activated, compared with the mgrB loss-of-function mutant P23 are presented as mean ± standard error of the mean. PmrA, B, and C were significantly upregulated relative to KP47 in its PmrB* mutant based on a t test (P < 0.05). No other differences were statistically significant.

Little evidence for PhoPQ-PmrD-PmrAB-mediated signal transduction for in vitro colistin resistance in K. pneumoniae.As shown above, disruption of pmrD or pmrA in an mgrB loss-of-function mutant did not reduce Arn protein production below a threshold required for colistin resistance (Fig. 2, Table 1). It was also interesting to find that PmrA, B, or C were not produced above our limit of detection (around 100 times less than the level seen in the PmrB* mutant) in any mgrB loss-of-function mutant or in the PhoQ* mutant (Fig. 4). These two findings lead us to conclude that cross activation of PmrAB (the direct regulator of pmrC) following activation of PhoPQ is very limited under the growth conditions used for our analysis.

Our observation that the phosphoethanolamine transferase PmrC is unique to the PmrAB-mediated branch of the colistin resistance-mediating regulatory system may well explain why, of multiple studies monitoring the impact of mgrB loss-of-function on lipopolysaccharide modification in K. pneumoniae (11–13, 29), only one has reported elevated levels of phosphoethanolamine modification (29). Indeed, even in this case, contrary to expectations, the observed modification, and the observed upregulation of pmrC expression were both apparently dependent on PhoPQ but not PmrAB, suggesting it was not caused by PhoPQ-PmrD-PmrAB cross-regulation at all (29). Furthermore, the authors showed that pmrC disruption in an mgrB loss-of-function mutant background only had a small impact on survival in the presence of colistin (29). This implies that even when rarely seen, phosphoethanolamine modification by PmrC has only a minor role in colistin resistance in K. pneumoniae. Indeed, an absence of phosphoethanolamine modification has been advocated as a way to identify mutational colistin resistance (as opposed to mcr-mediated resistance, which does cause this modification), whether due to mgrB loss-of-function mutation, PhoPQ activation, or PmrAB activation in K. pneumoniae (30).

The reason why other earlier seminal reports have placed far higher importance on the cross-activation of PmrAB by PhoPQ via PmrD in K. pneumoniae (14, 18) could be that they used growth media that caused greater basal activation of PmrAB. It is important to remember that the PmrD linker protein has only experimentally been shown to increase the activation of PmrAB once PmrAB has been activated by an external signal, not to activate PmrAB from the basal state (14, 18). Since PmrAB activation is affected by iron concentration and pH, it may be that the medium used for colistin susceptibility testing—and used by us here—does not activate PmrAB in the first place, so there is nothing that PmrD can do to enhance activation, effectively silencing the cross-regulatory pathway. Indeed, it is worth noting that in some Enterobacteriaceae species, e.g., Enterobacter cloacae, there is no pmrD gene and PhoPQ and PmrAB work independently to regulate arn operon transcription (31).

Another explanation for differences between the conclusions of our own and previous work is that previous work relied on measurements of transcript levels. In some cases, small changes in protein abundance are associated with phenotypically relevant changes in antimicrobial susceptibility, as we have shown previously in K. pneumoniae, such as with loss-of-function mutations in ramR, which, despite having <5-fold effects on OmpK35 porin and AcrAB-TolC efflux pump production, have large effects on susceptibility to a range of antimicrobial agents from different classes (32). But in some cases, large changes in gene expression are required to have a phenotypic effect when a gene is not highly expressed in the wild type, for example in the case of OqxAB efflux pump production as controlled by OqxR in K. pneumoniae, which needs to increase >10,000-fold to have a phenotypic effect on resistance (33). One major advantage of proteomics is that comparisons of protein abundance can be drawn between different gene products, which is not always the case when transcript levels are measured, since the kinetics of DNA hybridization can have major influences on signal. This advantage is exemplified here in the context of PmrE production, which we find to be constitutive in K. pneumoniae and not part of the PhoPQ or PmrAB regulons (Fig. 4). In contrast, it is controlled by both regulators in Salmonella spp. (5). In the context of PmrB activation in K. pneumoniae, constitutive expression of pmrE has also been shown by reverse transcriptase quantitative PCR (qRT-PCR) (26) and in the context of CrrB activation—leading to PmrAB activation—this has been shown through transcriptomics (20). The added value of proteomics is that we can conclude that PmrE, which is an enzyme responsible for driving the committed step for the biosynthesis of 4-amino-4-deoxy-l-arabinose required for colistin resistance (5), is present at levels in wild-type cells similar to the levels of Arn protein produced in colistin-resistant mutants, rather than its production being constitutive but at low levels (Fig. 3 and 4).

Conclusions. We conclude that colistin resistance caused by PhoPQ activation in conditions defined for colistin susceptibility testing, i.e., in most clinical cases (28), is due almost exclusively to direct Arn protein upregulation. While PmrAB activation can also cause Arn protein upregulation and colistin resistance, there is no evidence for significant activation of PmrAB via PmrD as an additional mechanism for upregulating Arn proteins following PhoPQ activation under these growth conditions. We also conclude that the level of Arn protein upregulation dictates colistin MICs. It is interesting to note, therefore, that clinical isolates with multiple mutations activating PhoPQ can be found, where there is an additive effect on colistin MIC (28). The implication is that real-world colistin usage in the clinic in some cases selects for mutations or combinations of mutations that confer colistin MICs above the currently defined resistance breakpoint.

MATERIALS AND METHODS

Materials, bacterial isolates, selection and generation of mutants.Chemicals were from Sigma and growth media from Oxoid, unless otherwise stated. Strains used were K. pneumoniae Ecl8 (34), plus the clinical isolate KP47 (35). To select colistin-resistant mutants, 100-μl aliquots of overnight cultures of the parent strain grown in cation-adjusted Muller-Hinton broth (CAMHB) were spread onto Mueller-Hinton agar containing 32 μg · ml−1 colistin, which were then incubated for 24 h. Insertional inactivation of phoP, pmrD, or pmrA was performed using the pKNOCK suicide plasmid (36). The phoP, pmrD, and pmrA DNA fragments were amplified with Phusion High-Fidelity DNA polymerase (NEB, UK) from K. pneumoniae Ecl8 genomic DNA by using primers listed in Table S2. Each PCR product was ligated into the pKNOCK-GM at the SmaI site. The recombinant plasmid was then transferred into K. pneumoniae cells by conjugation. Mutants were selected for gentamicin nonsusceptibility (5 μg · ml−1) and the mutation was confirmed by PCR using primers listed in Table S2.

Determining MICs of colistin.MICs were determined using CLSI broth microtiter assays (37) and interpreted using published breakpoints (38). Briefly, a phosphate-buffered saline (PBS) bacterial suspension was prepared to obtain a stock of optical density at 600 nm (OD600) = 0.01. The final volume in each well of a 96-well cell culture plate (Corning Costar) was 200 μl and included 20 μl of the bacterial suspension. Bacterial growth was determined after 20 h of incubation by measuring OD600 values using a POLARstar Omega spectrophotometer (BMG Labtech).

Proteomics.Overnight CAMHB cultures (500 μl) were transferred to 50 ml of CAMHB and cells were grown at 37°C to 0.6 OD600. Cells were pelleted by centrifugation (10 min, 4,000 × g, 4°C) and resuspended in 30 ml of 30 mM Tris-HCl, pH 8, and broken by sonication using a cycle of 1 s on, 0.5 s off, for 3 min at an amplitude of 63% using a Sonics Vibracell VC-505TM (Sonics and Materials Inc., Newton, CT, USA). The sonicated samples were centrifuged at 8,000 rpm (Sorval RC5B PLUS using an SS-34 rotor) for 15 min at 4°C to pellet intact cells and large cell debris. For envelope preparations, the supernatant was subjected to centrifugation at 20,000 rpm for 60 min at 4°C using the above rotor to pellet total envelopes. To isolate total envelope proteins, this total envelope pellet was solubilized using 200 μl of 30 mM Tris-HCl pH 8 containing 0.5% (wt/vol) SDS.

Liquid chromatography-tandem mass spectrometry (LC-MS-MS) shotgun proteomic analysis was performed as described previously (32). Analysis was repeated three times for each parent and mutant strain, each using a separate batch of cells. Specific protein abundance was normalized based on the average abundance of the 50 most abundant proteins in each sample. Comparisons of normalized abundance between samples used an unpaired t test, and significance was defined with P < 0.05. Fold change in abundance between strains was calculated by first calculating average normalized abundance across the three samples representing each strain.

Whole-genome sequencing to identify mutations.Whole-genome resequencing was performed by MicrobesNG (Birmingham, UK) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using Trimmomatic (39) and assembled into contigs using SPAdes 3.10.1 (http://cab.spbu.ru/software/spades/). Assembled contigs were mapped to the K. pneumoniae Ecl8 reference genome (GenBank accession number GCF_000315385.1) (34), obtained from GenBank by using progressive Mauve alignment software (40).

ACKNOWLEDGMENTS

This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. Genome sequencing was provided by MicrobesNG (http://www.microbesng.uk/), which is supported by the BBSRC (grant number BB/L024209/1).

We declare no conflicts of interest.

FOOTNOTES

    • Received 22 April 2020.
    • Returned for modification 6 May 2020.
    • Accepted 19 May 2020.
    • Accepted manuscript posted online 26 May 2020.
  • Supplemental material is available online only.

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Durante-Mangoni E,
    2. Andini R,
    3. Zampino R
    . 2019. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect 25:943–950. doi:10.1016/j.cmi.2019.04.013.
    OpenUrlCrossRef
  2. 2.↵
    1. Tóth A,
    2. Damjanova I,
    3. Puskás E,
    4. Jánvári L,
    5. Farkas M,
    6. Dobák A,
    7. Böröcz K,
    8. Pászti J
    . 2010. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 29:765–769. doi:10.1007/s10096-010-0921-3.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Kontopoulou K,
    2. Protonotariou E,
    3. Vasilakos K,
    4. Kriti M,
    5. Koteli A,
    6. Antoniadou E,
    7. Sofianou D
    . 2010. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect 76:70–73. doi:10.1016/j.jhin.2010.03.021.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Elemam A,
    2. Rahimian J,
    3. Doymaz M
    . 2010. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 48:3558–3562. doi:10.1128/JCM.01106-10.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Jeannot K,
    2. Bolard A,
    3. Plésiat P
    . 2017. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 49:526–535. doi:10.1016/j.ijantimicag.2016.11.029.
    OpenUrlCrossRef
  6. 6.↵
    1. Deshpande LM,
    2. Hubler C,
    3. Davis AP,
    4. Castanheira M
    . 2019. Updated prevalence of mcr-like genes among Escherichia coli and Klebsiella pneumoniae in the SENTRY program and characterization of mcr-1.11 variant. Antimicrob Agents Chemother 63:e02450-18. doi:10.1128/AAC.02450-18.
    OpenUrlFREE Full Text
  7. 7.↵
    1. Cannatelli A,
    2. D'Andrea MM,
    3. Giani T,
    4. Di Pilato V,
    5. Arena F,
    6. Ambretti S,
    7. Gaibani P,
    8. Rossolini GM
    . 2013. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 57:5521–5526. doi:10.1128/AAC.01480-13.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. López-Camacho E,
    2. Gómez-Gil R,
    3. Tobes R,
    4. Manrique M,
    5. Lorenzo M,
    6. Galván B,
    7. Salvarelli E,
    8. Moatassim Y,
    9. Salanueva IJ,
    10. Pareja E,
    11. Codoñer FM,
    12. Alvarez-Tejado M,
    13. Garcillán-Barcia MP,
    14. De la Cruz F,
    15. Mingorance J
    . 2014. Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin resistance. J Antimicrob Chemother 69:632–636. doi:10.1093/jac/dkt419.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Cannatelli A,
    2. Giani T,
    3. D'Andrea MM,
    4. Di Pilato V,
    5. Arena F,
    6. Conte V,
    7. Tryfinopoulou K,
    8. Vatopoulos A,
    9. Rossolini GM, COLGRIT Study Group
    . 2014. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin. Antimicrob Agents Chemother 58:5696–5703. doi:10.1128/AAC.03110-14.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Poirel L,
    2. Jayol A,
    3. Bontron S,
    4. Villegas MV,
    5. Ozdamar M,
    6. Türkoglu S,
    7. Nordmann P
    . 2015. The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother 70:75–80. doi:10.1093/jac/dku323.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Helander IM,
    2. Kato Y,
    3. Kilpeläinen I,
    4. Kostiainen R,
    5. Lindner B,
    6. Nummila K,
    7. Sugiyama T,
    8. Yokochi T
    . 1996. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. Eur J Biochem 237:272–278. doi:10.1111/j.1432-1033.1996.0272n.x.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Leung LM,
    2. Cooper VS,
    3. Rasko DA,
    4. Guo Q,
    5. Pacey MP,
    6. McElheny CL,
    7. Mettus RT,
    8. Yoon SH,
    9. Goodlett DR,
    10. Ernst RK,
    11. Doi Y
    . 2017. Structural modification of LPS in colistin-resistant, KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 72:3035–3042. doi:10.1093/jac/dkx234.
    OpenUrlCrossRef
  13. 13.↵
    1. Jasim R,
    2. Baker MA,
    3. Zhu Y,
    4. Han M,
    5. Schneider-Futschik EK,
    6. Hussein M,
    7. Hoyer D,
    8. Li J,
    9. Velkov T
    . 2018. A comparative study of outer membrane proteome between paired colistin-susceptible and extremely colistin-resistant Klebsiella pneumoniae strains. ACS Infect Dis 4:1692–1704. doi:10.1021/acsinfecdis.8b00174.
    OpenUrlCrossRef
  14. 14.↵
    1. Mitrophanov AY,
    2. Jewett MW,
    3. Hadley TJ,
    4. Groisman EA
    . 2008. Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. PLoS Genet 4:e1000233. doi:10.1371/journal.pgen.1000233.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Humphries RM,
    2. Green DA,
    3. Schuetz AN,
    4. Bergman Y,
    5. Lewis S,
    6. Yee R,
    7. Stump S,
    8. Lopez M,
    9. Macesic N,
    10. Uhlemann AC,
    11. Kohner P,
    12. Cole N,
    13. Simner PJ
    . 2019. Multicenter evaluation of colistin broth disk elution and colistin agar test: a report from the Clinical and Laboratory Standards Institute. J Clin Microbiol 57:e01269-19. doi:10.1128/JCM.01269-19.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Carretto E,
    2. Brovarone F,
    3. Russello G,
    4. Nardini P,
    5. El-Bouseary MM,
    6. Aboklaish AF,
    7. Walsh TR,
    8. Tyrrell JM
    . 2018. Clinical validation of SensiTest Colistin, a broth microdilution-based method to evaluate colistin MICs. J Clin Microbiol 56:e01523-17. doi:10.1128/JCM.01523-17.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    CLSI-EUCAST Polymyxin Breakpoints Working Group. 2016. Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. EUCAST http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf.
  18. 18.↵
    1. Cheng HY,
    2. Chen YF,
    3. Peng HL
    . 2010. Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43. J Biomed Sci 17:60. doi:10.1186/1423-0127-17-60.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Lippa AM,
    2. Goulian M
    . 2009. Feedback inhibition in the PhoQ/PhoP signaling system by a membrane peptide. PLoS Genet 5:e1000788. doi:10.1371/journal.pgen.1000788.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Wright MS,
    2. Suzuki Y,
    3. Jones MB,
    4. Marshall SH,
    5. Rudin SD,
    6. van Duin D,
    7. Kaye K,
    8. Jacobs MR,
    9. Bonomo RA,
    10. Adams MD
    . 2015. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother 59:536–543. doi:10.1128/AAC.04037-14.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Halaby T,
    2. Kucukkose E,
    3. Janssen AB,
    4. Rogers MR,
    5. Doorduijn DJ,
    6. van der Zanden AG,
    7. Al Naiemi N,
    8. Vandenbroucke-Grauls CM,
    9. van Schaik W
    . 2016. Genomic characterization of colistin heteroresistance in Klebsiella pneumoniae during a nosocomial outbreak. Antimicrob Agents Chemother 60:6837–6843. doi:10.1128/AAC.01344-16.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Jayol A,
    2. Nordmann P,
    3. Brink A,
    4. Poirel L
    . 2015. Heteroresistance to colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system. Antimicrob Agents Chemother 59:2780–2784. doi:10.1128/AAC.05055-14.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Cannatelli A,
    2. Di Pilato V,
    3. Giani T,
    4. Arena F,
    5. Ambretti S,
    6. Gaibani P,
    7. D'Andrea MM,
    8. Rossolini GM
    . 2014. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment. Antimicrob Agents Chemother 58:4399–4403. doi:10.1128/AAC.02555-14.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Jayol A,
    2. Poirel L,
    3. Brink A,
    4. Villegas MV,
    5. Yilmaz M,
    6. Nordmann P
    . 2014. Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin. Antimicrob Agents Chemother 58:4762–4766. doi:10.1128/AAC.00084-14.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Lee H,
    2. Hsu FF,
    3. Turk J,
    4. Groisman EA
    . 2004. The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica. J Bacteriol 186:4124–4133. doi:10.1128/JB.186.13.4124-4133.2004.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Cheng YH,
    2. Lin TL,
    3. Lin YT,
    4. Wang JT
    . 2016. Amino acid substitutions of CrrB responsible for resistance to colistin through CrrC in Klebsiella pneumoniae. Antimicrob Agents Chemother 60:3709–3716. doi:10.1128/AAC.00009-16.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Jayol A,
    2. Nordmann P,
    3. Brink A,
    4. Villegas MV,
    5. Dubois V,
    6. Poirel L
    . 2017. High-level resistance to colistin mediated by various mutations in the crrB gene among carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61:e01423-17. doi:10.1128/AAC.01423-17.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Macesic N,
    2. Nelson B,
    3. Mcconville TH,
    4. Giddins MJ,
    5. Green DA,
    6. Stump S,
    7. Gomez-Simmonds A,
    8. Annavajhala MK,
    9. Uhlemann AC
    . 2020. Emergence of polymyxin resistance in clinical Klebsiella pneumoniae through diverse genetic adaptations: a genomic, retrospective cohort study. Clin Infect Dis 70:2084–2091. doi:10.1093/cid/ciz623.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Kidd TJ,
    2. Mills G,
    3. Sá-Pessoa J,
    4. Dumigan A,
    5. Frank CG,
    6. Insua JL,
    7. Ingram R,
    8. Hobley L,
    9. Bengoechea JA
    . 2017. A Klebsiella pneumoniae antibiotic resistance mechanism that subdues host defences and promotes virulence. EMBO Mol Med 9:430–447. doi:10.15252/emmm.201607336.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Dortet L,
    2. Broda A,
    3. Bernabeu S,
    4. Glupczynski Y,
    5. Bogaerts P,
    6. Bonnin R,
    7. Naas T,
    8. Filloux A,
    9. Larrouy-Maumus G
    . 2020. Optimization of the MALDIxin test for the rapid identification of colistin resistance in Klebsiella pneumoniae using MALDI-TOF MS. J Antimicrob Chemother 75:110–116. doi:10.1093/jac/dkz405.
    OpenUrlCrossRef
  31. 31.↵
    1. Guérin F,
    2. Isnard C,
    3. Sinel C,
    4. Morand P,
    5. Dhalluin A,
    6. Cattoir V,
    7. Giard JC
    . 2016. Cluster-dependent colistin hetero-resistance in Enterobacter cloacae complex. J Antimicrob Chemother 71:3058–3061. doi:10.1093/jac/dkw260.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Jiménez-Castellanos JC,
    2. Wan Nur Ismah WAK,
    3. Takebayashi Y,
    4. Findlay J,
    5. Schneiders T,
    6. Heesom KJ,
    7. Avison MB
    . 2018. Envelope proteome changes driven by RamA overproduction in Klebsiella pneumoniae that enhance acquired β-lactam resistance. J Antimicrob Chemother 73:88–94. doi:10.1093/jac/dkx345.
    OpenUrlCrossRef
  33. 33.↵
    1. Wan Nur Ismah WAK,
    2. Takebayashi Y,
    3. Findlay J,
    4. Heesom KJ,
    5. Avison MB
    . 2018. Impact of OqxR loss of function on the envelope proteome of Klebsiella pneumoniae and susceptibility to antimicrobials. J Antimicrob Chemother 73:2990–2996. doi:10.1093/jac/dky293.
    OpenUrlCrossRef
  34. 34.↵
    1. Fookes M,
    2. Yu J,
    3. De Majumdar S,
    4. Thomson N,
    5. Schneiders T
    . 2013. Genome sequence of Klebsiella pneumoniae Ecl8, a reference strain for targeted genetic manipulation. Genome Announc 1:e00027-12. doi:10.1128/genomeA.00027-12.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Wan Nur Ismah WAK,
    2. Takebayashi Y,
    3. Findlay J,
    4. Heesom KJ,
    5. Jiménez-Castellanos JC,
    6. Zhang J,
    7. Graham L,
    8. Bowker K,
    9. Williams OM,
    10. MacGowan AP,
    11. Avison MB
    . 2017. Prediction of fluoroquinolone susceptibility directly from whole-genome sequence data by using liquid chromatography-tandem mass spectrometry to identify mutant genotypes. Antimicrob Agents Chemother 62:e01814-17. doi:10.1128/AAC.01814-17.
    OpenUrlCrossRef
  36. 36.↵
    1. Alexeyev MF
    . 1999. The pKNOCK series of broad-host-range mobilizable suicide vectors for gene knockout and targeted DNA insertion into the chromosome of Gram-negative bacteria. Biotechniques 26:824–828. doi:10.2144/99265bm05.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed Clinical and Laboratory Standards Institute, Wayne, PA.
  38. 38.↵
    Clinical and Laboratory Standards Institute. 2019. M100-S29. Performance standards for antimicrobial susceptibility testing; twenty-ninth informational supplement. An informational supplement for global application developed through the Clinical and Laboratory Standards Institute consensus process. Clinical and Laboratory Standards Institute, Wayne, PA.
  39. 39.↵
    1. Bolger AM,
    2. Lohse M,
    3. Usadel B
    . 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. doi:10.1093/bioinformatics/btu170.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Darling AE,
    2. Mau B,
    3. Perna NT,
    4. Batzoglou S,
    5. Zhong Y
    . 2010. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One 5:e11147. doi:10.1371/journal.pone.0011147.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Proteomic Investigation of the Signal Transduction Pathways Controlling Colistin Resistance in Klebsiella pneumoniae
Ching Hei Phoebe Cheung, Punyawee Dulyayangkul, Kate J. Heesom, Matthew B. Avison
Antimicrobial Agents and Chemotherapy Jul 2020, 64 (8) e00790-20; DOI: 10.1128/AAC.00790-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Proteomic Investigation of the Signal Transduction Pathways Controlling Colistin Resistance in Klebsiella pneumoniae
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Proteomic Investigation of the Signal Transduction Pathways Controlling Colistin Resistance in Klebsiella pneumoniae
Ching Hei Phoebe Cheung, Punyawee Dulyayangkul, Kate J. Heesom, Matthew B. Avison
Antimicrobial Agents and Chemotherapy Jul 2020, 64 (8) e00790-20; DOI: 10.1128/AAC.00790-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS AND DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

polymyxins
two-component regulatory systems

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596